CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) Files An 8-K Other Events
ITEM 8.01 OTHER EVENTS.

On July 21, 2017, China Biologic Products, Inc., a Delaware corporation (the “Company”), completed the redomicile merger to reorganize itself as a Cayman Islands company. to the agreement and plan of merger dated as of April 28, 2017 (the “Merger Agreement”), the Company has merged with and into China Biologic Products Holdings, Inc., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company (“CBPO Cayman”), with CBPO Cayman as the surviving company. Each issued and outstanding share of the common stock of the Company was converted into the right to receive one ordinary share of CBPO Cayman. CBPO Cayman’s ordinary shares will be listed on NASDAQ under the symbol “CBPO” effective July 24, 2017.

The information contained in this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Safe Harbor Statement

This report contains certain “forward-looking statements” relating to the Company and CBPO Cayman, including statements regarding the listing of CBPO Cayman’s ordinary shares on NASDAQ. These statements are forward-looking in nature and subject to risks and uncertainties that may cause actual results to differ materially. All forward-looking statements included in this report are based upon information available to the Company and CBPO Cayman as of the date of this report, which may change, and the Company and CBPO Cayman undertake no obligation to update or revise any forward-looking statements, except as may be required under applicable securities law.

About CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO)

China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories. Its principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through approximately two subsidiaries, namely, Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co., Ltd., a plasma products company. Its products also include Human rabies immunoglobulin, Human tetanus immunoglobulin, Placenta polypeptide, Factor VIII and Human prothrombin complex concentrate.